Minervasäätiö

Minervasäätiö

Minervasäätiö was formed in 1959 by University of Helsinki medical faculty — notably Professors Bror-Axel Lamberg, Wolmar Nyberg and Ralph Gräsbeck — to pool research grants and rent laboratory space. The foundation’s primary statutory purpose is maintaining the Minerva Foundation Institute for Medical Research, housed within the Biomedicum Helsinki research center it co-owns with the University of Helsinki, Folkhälsan, and HUS Helsinki University Hospital. Today the foundation operates a strategy split between direct real assets and a diversified securities portfolio. The real asset side includes its long-held equity in the Kiinteistö Oy Biomedicum Helsinki properties at Haartmaninkatu 8 and Tukholmankatu 8. The securities portfolio grew out of the 2016 majority sale of the Medix enterprises — Yhtyneet Medix Laboratories and Medix Biochemica — which was executed alongside Folkhälsan and the Liv och Hälsa Society, with subsequent reinvestment through a DevCo-managed continuation vehicle that drew co-investment from Antti Herlin, the C. Ehrnrooth family, and Rettig Group. Proceeds from the 2016 divestiture were redirected into a stock-market portfolio; dividends from that portfolio now represent the Institute’s primary operating-income stream. The foundation’s geographic footprint concentrates in Finland, with Helsinki serving as both governance hub and research site. The governance structure separates fiduciary oversight from scientific direction. A five-member Board of Trustees, chaired by Professor Patrik Finne, is paired with a four-member Financial Committee led by Kim Karhu, and a six-member Scientific Committee chaired by Professor Per-Henrik Groop. Agent Patrik Lerche manages day-to-day administrative contact from the Jätkäsaarenkuja office. Financial committee members include Roger Lönnberg, bringing additional markets experience. The foundation participates in the Association of Finnish Foundations (Säätiöt ja rahastot), the national representative body for grant-making entities. In January 2026, the foundation awarded the Bror Axel Lamberg Prize to Professor Outi Mäkitie, continuing an annual grant cycle that also includes the Selma ja Maja-Lisa Selanderin rahasto. Minervasäätiö’s structural differentiator is its origin story: an academic research collective whose ancillary diagnostic lab — spun out as Medix — became the economic engine that now sustains pure research. This path, from pooled professorial stipends to a co-owned commercial real estate asset and a liquid market portfolio, produces a foundation balance sheet with no external fundraising pressure. The permanent-capital structure allows the Institute to maintain multi-decade research lines without grant-cycle disruption, a posture rare among European medical foundations.